Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Descripción general del informe

The global cancer vaccine market size was valued at USD 8.94 Billion in 2025 , driven by increasing initiatives from pharmaceutical giants to develop the most effective cancer vaccine. The market size is projected to grow at a CAGR of 11.80% during the forecast period 2026-2035 to reach a value of USD 27.27 Billion by 2035 .

Tasa de crecimiento anual compuesta

11.8%

Valorar USD Billion

2026-2035


Overview of the global cancer vaccines market

The market is driven by researchers who dedicate their efforts to discovering innovative combinations and developing effective vaccines against various types of cancer. Demand in the cancer vaccine market is fueled by the increasing prevalence of cancer cases globally. In 2023, approximately 20 million new cancer cases were diagnosed, and nearly 10 million deaths were recorded worldwide. The cancer burden is projected to increase by approximately 60% over the next two decades, placing greater pressure on healthcare systems, individuals, and communities. The global burden is projected to reach approximately 30 million new cancer cases by 2040, with a high incidence in low- and middle-income countries. As a result, industry leaders are joining forces to collaborate, conduct clinical trials, and develop cancer vaccine candidates.

Increased adoption of innovative alternatives to provide precise treatment

In August 2023, the National Health Service (NHS) in England, the UK's public healthcare system, launched a cancer vaccine that can reduce treatment time for some patients by three-quarters. Atezolizumab (Tencentriq®), an immunotherapy drug, has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and is administered intravenously in about 7 minutes, a significant reduction from conventional treatment time.

The launch of this injection is good news for both patients and healthcare providers, as it allows oncologists to administer treatment more quickly and conveniently. This approach is likely to contribute to greater patient awareness and deliver significant growth in the cancer vaccine market over the forecast period. The NHS's rapid adoption of this innovation demonstrates its commitment to improving the efficiency of healthcare services.

Strategic collaborations between market players

In October 2023, BioNTech SE announced that Autogene cevumeran (also known as BNT122, RO7198457), a targeted therapeutic vaccine candidate for the treatment of pancreatic ductal adenocarcinoma (PDAC), had advanced to Phase 2 trials after showing promising results in Phase 1 clinical trials. In Phase 2, the efficacy of cevumeran will be evaluated in 260 patients, in combination with the anti-PD-L1 immune checkpoint inhibitor atezolizumab and chemotherapy. The combination treatment will be compared to the current standard of care (mFOLFIRINOX).

The candidate is being jointly developed by BioNTech and Genentech (a member of the Roche Group) and is based on the mRNA-based neoantigen-specific individualized immunotherapy (iNeST) platform. This alliance of leading companies to design enhanced and personalized solutions is a significant market trend that is expected to positively influence the market share of cancer vaccines during the forecast period.

Segmentation of the global cancer vaccines market

El informe y previsión sobre el mercado de las vacunas contra el cáncer 2026-2035 ofrece un análisis detallado del mercado basado en los siguientes segmentos:

Desglose del mercado por tecnología

  • Vacunas recombinantes contra el cáncer
  • Vacunas contra el cáncer de células completas
  • Vacunas contra el cáncer con vectores virales y DNA
  • Otras tecnologías

Desglose del mercado por tipo de vacuna

  • Vacuna preventiva
  • Vacuna terapéutica

Desglose del mercado por aplicación

  • Cáncer de próstata
  • Cáncer de cuello uterino
  • Melanoma
  • Cáncer de vejiga
  • Otras aplicaciones

Desglose del mercado por región

  • América del Norte
  • Europa
  • Asia-Pacífico
  • América Latina
  • Oriente Medio y África

Regional analysis of the global cancer vaccines market

From a geographic perspective, North America is expected to dominate the market during the forecast period. In 2023, the region recorded 609,280 cancer-related deaths. According to the National Cancer Institute, an estimated 2 million people in the United States will be diagnosed with cancer in 2024. By 2040, the number of people diagnosed with cancer will increase by 57%, affecting approximately 6.23 million individuals. As a result, significant emphasis has been placed on developing effective solutions for preventing cancer-related deaths.

Europe holds a significant market share in cancer vaccines, thanks to the presence of leading academic and research institutions, coupled with substantial funding for research activities. Increasing collaboration between healthcare companies and academic institutions is expected to drive significant market growth in the region. The Asia-Pacific region is also experiencing growth, which can be attributed to the increasing integration of modern technologies into the medical ecosystem. Growing efforts by emerging market governments to improve infrastructure are another notable market trend in the region.

Global cancer vaccine market: competitive landscape

In February 2023, Moderna, Inc. and Merck announced that the FDA had granted Breakthrough Therapy designation to mRNA-4157/V940 in combination with pembrolizumab (Keytruda) for the adjuvant treatment of patients with high-risk melanoma following complete resection. The designation was based on positive results from the Phase 2b KEYNOTE-942 trial (NCT03897881). mRNA-4157/V940 is a novel, investigational, personalized cancer vaccine based on messenger ribonucleic acid (mRNA), composed of a single synthetic mRNA that encodes up to 34 neoantigens. It works by eliciting an innate immune response and generating specific T-cell responses.

Key features of the cancer vaccines market report include patent analysis, grant analysis, clinical trial analysis, funding and investment analysis, partnerships, and collaboration analysis of key players. The leading companies in the market are as follows:

  • Merck & Co., Inc.
  • GlaxoSmithKline plc.
  • Dendroon Pharmaceuticals LLC
  • Bristol Myers Squibb Company
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Sanofi
  • Pfizer Inc.
  • Gilead Sciences, Inc.
  • Inovio Pharmaceuticals
  • Bavarian Nordic
  • CureVac SE
  • Takeda Pharmaceutical Company Limited
  • Cascadian Therapeutics 

Please note that this is only a partial list of companies and the full list is included in the report.

*Si bien nos esforzamos por brindarle siempre información actual y precisa, los números representados en el sitio web son indicativos y pueden diferir de los números reales en el informe principal. En Expert Market Research, nuestro objetivo es brindarle las últimas ideas y tendencias en el mercado. Utilizando nuestros análisis y pronósticos, las partes interesadas pueden comprender la dinámica del mercado, navegar los desafíos y capitalizar las oportunidades para tomar decisiones estratégicas basadas en datos.*

Preguntas frecuentes sobre este informe

El mercado alcanzó un valor aproximado de USD 8.94 Billion en 2025, impulsado por el aumento de la incidencia del cáncer en todo el mundo.

Se prevé que el mercado crezca a una tasa compuesta anual (CAGR) del 11.80 % durante el periodo de previsión de 2026-2035 y que alcance un valor de mercado de USD 27.27 Billion en 2035.

La creciente concienciación de la población sobre las vacunas personalizadas contra el cáncer, el aumento de las actividades de investigación sobre la incidencia, los ensayos clínicos, el lanzamiento de vacunas y las aprobaciones de la FDA están impulsando la demanda del mercado.

Las empresas farmacéuticas están tomando numerosas iniciativas para colaborar y desarrollar las vacunas contra el cáncer más eficaces, lo que constituye una importante tendencia del mercado. En octubre de 2023, BioNTech SE reveló que Autogene cevumeran (también conocido como BNT122, RO7198457), una vacuna terapéutica individualizada contra el cáncer candidata para el tratamiento del adenocarcinoma ductal pancreático (PDAC) desarrollada por una asociación entre BioNTech y Genentech, pasó a la fase 2 de los ensayos tras mostrar resultados prometedores en los ensayos clínicos de fase 1.

Las principales regiones del mercado son América del Norte, Europa, Asia-Pacífico, América Latina, Oriente Medio y África. América del Norte lidera actualmente el mercado mundial.

Las tecnologías incluidas son vacunas recombinantes contra el cáncer, vacunas contra el cáncer de células completas, vacunas contra el cáncer con vectores virales y DNA, y otras tecnologías.

Los tipos comunes de vacunas contra el cáncer incluyen vacunas preventivas y vacunas terapéuticas.

Las áreas de aplicación comunes incluyen el cáncer de próstata y el cáncer de cuello uterino, entre otros.

Los principales actores que participan en el mercado son Merck & Co., Inc., GlaxoSmithKline plc., Dendreon Pharmaceuticals LLC, Bristol Myers Squibb Company, AstraZeneca, F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi, Pfizer Inc., Gilead Sciences, Inc., Inovio Pharmaceuticals, Bavarian Nordic, CureVac SE, Takeda Pharmaceutical Company Limited y Cascadian Therapeutics.

Resumen del informe

Explore nuestros aspectos clave del informe y obtenga una visión general concisa de los hallazgos clave, las tendencias y las ideas procesables que capacitarán sus decisiones estratégicas.

Lo más destacado del informe

Tenga en cuenta que las cifras mencionadas en la descripción sirven como estimaciones y pueden variar de las cifras reales presentadas en el informe final.

REPORT CHARACTERISTICS DETAILS
Base year 2025
Historical period 2019-2025
Forecast period 2026-2035
Scope of the report

Historical trends and forecasts, driving factors and limitations of the sector, historical analysis and market forecasts by segment:

  • Technology
  • Type of vaccine
  • Application
  • Region
Breakdown by technology
  • Recombinant cancer vaccines
  • Whole-cell cancer vaccines
  • Cancer vaccines using viral vectors and DNA
  • Other technologies
Breakdown by vaccine type
  • Preventive vaccine
  • Therapeutic vaccine
Breakdown by application
  • Prostate cancer
  • Cervical cancer
  • Melanoma Bladder cancer
  • Other applications
Breakdown by region
  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa
Market dynamics
  • Market drivers and restraints
  • SWOT Analysis
  • Porter's Five Forces Model
  • Key indicators of demand
  • Key price indicators
  • Events, initiatives and trends in the sector
  • Value chain analysis
Competitive landscape
  • Market structure
  • Company profiles
    • Financial analysis
    • Product portfolio
    • Demographic reach and achievements
    • Mergers and acquisitions
    • Certifications
Companies included
  • Merck & Co., Inc.
  • GlaxoSmithKline plc.
  • Dendroon Pharmaceuticals LLC
  • Bristol Myers Squibb Company
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd. 
  • Novartis AG
  • Sanofi
  • Pfizer Inc.
  • Gilead Sciences, Inc.
  • Inovio Pharmaceuticals
  • Bavarian Nordic
  • CureVac SE 
  • Takeda Pharmaceutical Company Limited
  • Cascadian Therapeutics

Datasheet

10 % Off

USD

3,299

2,969

Single User License

10 % Off

USD

5,499

4,949

Five User License

15 % Off

USD

6,999

5,949

Corporate License

15 % Off

USD

8,199

6,969

Datasheet

One User

USD 3,299

USD 2,969

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 5,499

USD 4,949

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 8,199

USD 6,969

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

Cómo ordenar

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Nuestra guía paso a paso lo ayudará a seleccionar, comprar y acceder a sus informes rápidamente, asegurando que obtenga la información que impulse sus decisiones, justo cuando la necesite.

License Type

Seleccione Tipo de licencia

Elija la licencia correcta para sus necesidades y derechos de acceso.

shopping cart

Haga clic en "Comprar ahora"

Agregue el informe a su carrito con un clic y proceda a registrarse.

Bookmark Icon

Seleccionar modo de pago

Elija una opción de pago para un pago seguro. Serás redirigido en consecuencia.

Soluciones estratégicas para la toma de decisiones informadas

Conectarse para más información

Nuestro equipo experto de analistas ofrecerá soporte total y resolverá cualquier consulta con respecto al informe, antes y después de la compra.

Nuestro equipo experto de analistas ofrecerá soporte total y resolverá cualquier consulta con respecto al informe, antes y después de la compra.

Empleamos métodos de investigación meticulosos, combinando análisis avanzados y ideas de expertos para ofrecer inteligencia de la industria precisa y procesable, manteniéndose por delante de los competidores.

Nuestros analistas calificados ofrecen una ventaja competitiva incomparable con ideas detalladas sobre los mercados actuales y emergentes, asegurando su ventaja estratégica.

Ofrecemos una presentación en profundidad pero simplificada de los conocimientos y análisis de la industria para cumplir con sus requisitos específicos de manera efectiva.

Estamos aquí para ayudar a responder cualquier pregunta sobre nuestros productos y servicios.

Contáctenos